Exhibit 10.27

 

Confidential Treatment Requested by Achaogen, Inc.

 

[g2018022720540565720702.jpg][g2018022720540566220702.jpg]          

November 29, 2017

 

Achaogen Inc.

Attn: Blake Wise, COO

1 Tower Place, #300

South San Francisco, CA 94080

 

 

Re:

Amendment #1 to the Collaborative Development & Commercialization Agreement
dated April 26, 2016 (“Agreement”)

 

Dear Blake:

 

As discussed between the parties, we are proposing the following amendments to
the Agreement which have been mutually agreed upon by the parties:

 

1.

Section 7.1 shall be deleted in its entirety and replaced with the following:

 

 

7.1

Development Payments.  In consideration of the development efforts of
Microgenics under the Research Program, Achaogen shall pay to Microgenics the
following one-time payments upon the occurrence of the corresponding events:  

 

 

(a)

USD $[***] upon the successful completion of Phase 0: [***] as determined in
accordance with the Project Plan, including delivery by Microgenics of all
deliverables required by the Project Plan for Phase 0;

 

 

(b)

USD $[***] upon the successful completion of Phase 1: [***] as determined in
accordance with the Project Plan, including delivery by Microgenics of all
deliverables required by the Project Plan for Phase 1;

 

 

(c)

USD $[***] upon the successful completion of Phase 2: [***] as determined in
accordance with the Project Plan, including delivery by Microgenics of all
deliverables required by the Project Plan for Phase 2;

 

 

(d)

USD $[***] upon the successful completion of Phase 3: [***] as determined in
accordance with the Project Plan, including delivery by Microgenics of all
deliverables required by the Project Plan for Phase 3;

 

 

 

Thermo Fisher Scientific

 

 

 

 

www.thermofisher.com

[***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

--------------------------------------------------------------------------------

Confidential Treatment Requested by Achaogen, Inc.

[g2018022720540565720702.jpg]

 

(e)

USD $[***] upon the successful completion of the first milestone of Phase
4:  [***] as determined in accordance with the Project Plan, including delivery
by Microgenics of all deliverables required by the Project Plan for the first
milestone of Phase 4;

 

An additional USD $[***] upon the successful completion of the first milestone
of Phase 4:  [***] of the Project Plan, [***].

 

 

(f)

USD $[***] upon the successful completion of the second milestone of Phase 4:
[***] as determined in accordance with the Project Plan, including delivery by
Microgenics of all deliverables required by the Project Plan for the second
milestone of Phase 4;

 

 

(g)

USD $[***] upon the successful completion of the third milestone of Phase 4:
[***] as determined in accordance with the Project Plan, including delivery by
Microgenics of all deliverables required by the Project Plan for the third
milestone of Phase 4;

 

An additional USD $[***] upon the successful completion of the third milestone
of Phase 4; [***] of the Project Plan, [***], and [***].  

 

 

(h)

[***], USD $[***] upon the successful completion of the fourth milestone of
Phase 4: [***] as determined in accordance with the Project Plan, including
delivery by Microgenics of all deliverables required by the Project Plan for the
fourth milestone of Phase 4;

 

 

(i)

USD $[***] upon the successful completion of the first milestone of Phase 5:
[***] as determined in accordance with the Project Plan, including delivery by
Microgenics of all deliverables required by the Project Plan for the first
milestone of Phase 5;

 

 

(j)

USD $[***] upon the successful completion of the second milestone of Phase 5:
[***] as determined in accordance with the Project Plan, including delivery by
Microgenics of all deliverables required by the Project Plan for the second
milestone of Phase 5;

 

 

(k)

[***]; and

 

 

(l)

[***] and assuming [***], USD $[***] upon [***]; provided, however, this amount
[***].

 

Thereafter, no additional payments shall be due and payable to Microgenics by
Achaogen for any Assay [***].

 

2.

Exhibit F shall be deleted in its entirety and replaced with the attached
Exhibit F-1.

All other terms and conditions related to the Agreement shall remain in full
force and effect.  

 

If you agree with these changes, please sign below and return an original and
electronic copy to me.

Page 2 of 4

[***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

--------------------------------------------------------------------------------

Confidential Treatment Requested by Achaogen, Inc.

[g2018022720540565720702.jpg]

 

Sincerely,

 

 

 

[***]

 

 

Agreed and accepted:

Microgenics CorporationAchaogen Inc.

 

 

/s/ [***]

 

/s/ [***]

Print Name: [***] Print Name: [***]

Title: [***]Title: [***]

 

Page 3 of 4

[***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

--------------------------------------------------------------------------------

Confidential Treatment Requested by Achaogen, Inc.

[g2018022720540565720702.jpg]

Exhibit F – 1

Project Plan Timeline and Deliverables

 

Plazomicin TDM Immunoassay Development Project Plan Timeline and Deliverables

 

Deliverables

Start

End

Duration (M)

Phase 0

[***]

[***]

[***]

[***]

•[***]

•[***]

Phase 1

[***] 

[***]

[***]

[***]

•[***]

•[***]

Phase 2

[***]

[***]

[***]

[***]

•[***]

•[***]

Phase 3

[***]

[***]

[***]

[***]

•[***]

 

•[***]

Phase 4

[***]

[***]

[***]

[***]

Milestone 1: [***]

[***]

[***]

[***]

•[***]  

Milestone 2: [***]

[***]

[***]

[***]

•[***]

Milestone 3: [***]

[***]

[***]

[***]

•[***]

[***]

[***]

[***]

[***]

[***]

•[***]

Phase 5

[***]

[***]

 

[***]

Milestone 1: [***]

[***]

[***]

[***]

[***]

Milestone 2: [***]

[***]

[***]

[***]

•[***]

 

 

Page 4 of 4

[***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.